A multicenter, randomized, double-blind, double dummy study comparing the efficacy and safety of Evogliptin with Sitagliptin in patients with type 2 diabetes mellitus receiving background therapy with Metformin

Trial Profile

A multicenter, randomized, double-blind, double dummy study comparing the efficacy and safety of Evogliptin with Sitagliptin in patients with type 2 diabetes mellitus receiving background therapy with Metformin

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Dec 2017

At a glance

  • Drugs Evogliptin (Primary) ; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Alkem Laboratories
  • Most Recent Events

    • 12 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top